Which hedge funds own MLTX? MOONLAKE IMMUNOTHERAPEUTICS, Q2 2026 13F holders
58 tracked hedge funds disclosed a position in MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in their Q2 2026 13F filings, worth $705.0m in total. The largest holder by portfolio weight is Lion Point Capital, LP at 6.3% of its book. 14 opened a new position this quarter: Trails Edge Capital Partners, LP, Stonepine Capital Management, LLC, Capricorn Fund Managers Ltd, Polymer Capital Management (HK) LTD. 5 exited: Ishara Investments LP, Casdin Capital, LLC, Avidity Partners Management LP.
- 58
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 14
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 5
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $41.5m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $15.9m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $705m
- Combined value Sum of the holders' reported positions in the security.
- 4.7%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Ishara Investments LP | 3.3% | $3.2m |
| Casdin Capital, LLC | 0.6% | $8.4m |
| Avidity Partners Management LP | 0.2% | $932k |
| Readystate Asset Management LP | 0.2% | $2.7m |
| Brevan Howard Capital Management LP | 0.01% | $606k |
Ownership over time
Who discovered MLTX first? Beta
The run: Q2 2022 → Q4 2023, ×12
| Cormorant Asset Management, LP high conviction | Q2 2022 | 2.4% | −1.8 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.